Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of a Daily Subcutaneous Treatment Regimen With Marzeptacog Alfa (Activated) for Bleeding Prophylaxis in Adult Subjects With Hemophilia A and B Subjects With an Inhibitor

NCT03407651 is registered in ClinicalTrials.gov with Catalyst Biosciences as lead sponsor.

NCT NCT03407651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03407651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of a Daily Subcutaneous Treatment Regimen With Marzeptacog Alfa (Activated) for Bleeding Prophylaxis in Adult Subjects With Hemophilia A and B Subjects With an Inhibitor
Lead sponsor
Catalyst Biosciences
Phase
Phase 2
Overall status
Completed
Start date
December 18, 2017
Completion date
April 13, 2019
Enrollment
11 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a with inhibitor, hemophilia b with inhibitor